Epitel, Inc., a leader in AI-driven wireless brain health technologies, announced today the closing of a $26 million Series B financing co-led by Catalyst Health Ventures and Genoa Ventures, with participation from new and existing investors. The funding will support the continued market expansion of the company’s REMI® Remote EEG Monitoring System, allowing extended duration wireless EEG monitoring integrated with AI-driven event detection to improve access to neurological care..

人工智能驱动无线脑健康技术领域的领导者Epitel, Inc.今日宣布完成2600万美元的B轮融资，本轮融资由Catalyst Health Ventures和Genoa Ventures联合领投，新老投资者均有参与。该笔资金将用于支持公司REMI®远程脑电图监测系统的持续市场扩张，通过集成人工智能驱动的事件检测功能，实现长时程无线脑电图监测，从而提升神经科医疗服务的可及性。

Epitel is initially focused on seizure detection and diagnosis. In the United States, 9.2 million Americans experience seizures annually, yet 40 percent lack access to EEG, in part because only 27 percent of U.S. hospitals have EEG capacity1. For many patients, diagnosis depends on capturing seizure activity on EEG, as most seizures do not manifest with outward clinical symptoms.

Epitel 最初专注于癫痫发作的检测与诊断。在美国，每年有 920 万美国人经历癫痫发作，然而 40% 的患者无法获得脑电图（EEG）检查，部分原因在于仅有 27% 的美国医院具备脑电图检测能力¹。对于许多患者而言，诊断依赖于通过脑电图捕捉癫痫发作活动，因为大多数癫痫发作并不表现出明显的临床症状。

Traditional EEG typically can only be used to monitor patients for up to three days (72 hours); however, seizures are rare, unpredictable events that may occur days or weeks apart. This means that achieving a proper diagnosis can take months or longer..

传统脑电图（EEG）通常仅能用于对患者进行长达三天（72小时）的监测；然而，癫痫发作是罕见且不可预测的事件，可能间隔数天或数周才发生一次。这意味着，要实现准确诊断可能需要数月甚至更长时间。

Epitel is addressing these challenges through the REMI™ portfolio, which has received five U.S. Food and Drug Administration 510(k) clearances across its wireless EEG monitoring and AI-driven event detection technologies. Using wireless, wearable sensors, the REMI Remote EEG Monitoring System enables monitoring of brain activity at home during everyday activities for several weeks, extending access to neurological care beyond traditional hospital or tethered settings.

Epitel 正通过其 REMI™ 产品组合应对这些挑战，该组合的无线脑电图（EEG）监测和人工智能驱动的事件检测技术已获得五项美国食品药品监督管理局（FDA）510(k) 许可。REMI 远程脑电图监测系统采用无线可穿戴传感器，能够在数周内对患者在日常生活中进行居家脑活动监测，从而将神经科护理的范围从传统的医院或有线连接环境扩展至更广泛的场景。

REMI Vigilenz™ AI For Event Detection analyzes REMI EEG to flag potential seizures, helping clinicians efficiently review extended-duration recordings and accelerate diagnosis by capturing objective evidence. The platform is cleared for neurological monitoring in patients as young as one year old, with AI-assisted event detection available for patients aged six and older, supporting Epitel’s goal of accessible EEG monitoring across all age groups..

REMI Vigilenz™ AI 事件检测系统通过分析 REMI EEG 数据来标记潜在的癫痫发作，帮助临床医生高效审查长时程记录，并通过捕捉客观证据加速诊断。该平台已获准用于低至一岁患者的神经监测，其中 AI 辅助事件检测功能适用于六岁及以上患者，从而支持 Epitel 实现面向所有年龄段的无障碍 EEG 监测目标。

'Millions of Americans with suspected seizures still face significant barriers to diagnosis because access to EEG remains limited, particularly outside major medical centers. We built the REMI System to help close that gap by bringing longer-term neurological monitoring closer to patients and helping clinicians efficiently review the data needed to make a diagnosis,' said Steve Pacelli, President & Chief Executive Officer of Epitel.

“数百万疑似癫痫发作的美国人仍然面临重大的诊断障碍，因为脑电图（EEG）的可及性依然有限，尤其是在大型医疗中心之外。我们开发了REMI系统，旨在通过将更长期的神经监测更贴近患者，并帮助临床医生高效审查做出诊断所需的数据，来缩小这一差距。”Epitel公司总裁兼首席执行官史蒂夫·帕切利表示。

'Closing this Series B round represents a pivotal milestone for our team. With these resources, we are aggressively building out our commercial footprint by expanding our dedicated field team to get REMI into the hands of those who will most benefit from it.'.

“完成本轮B轮融资对我们团队而言是一个关键的里程碑。借助这些资源，我们正在积极扩大商业布局，通过扩充专属的外勤团队，将REMI交付到最能从中受益的用户手中。”

The Series B capital will specifically fund the following initiatives:

B轮融资将专门用于资助以下举措：

Commercial Infrastructure Expansion

商业基础设施扩建

: Scaling the sales, marketing, and customer experience teams to accelerate adoption and access.

扩大销售、营销和客户体验团队的规模，以加速产品采用和市场渗透。

Provider Adoption:

供应商采纳：

Streamlining distribution and deployment models to help clinical teams integrate REMI smoothly into existing workflows.

简化分发和部署模式，帮助临床团队将REMI顺利整合到现有工作流程中。

Ambulatory Market Access Growth:

门诊市场准入增长：

With FDA clearance now extending to patients as young as one year of age, REMI brings the same long-term seizure monitoring previously available only in specialized centers to the youngest and most vulnerable patients.

随着美国食品药品监督管理局（FDA）的批准范围现已扩展至年仅一岁的患者，REMI 将此前仅在专业中心提供的长期癫痫发作监测服务，带给最年幼且最脆弱的患者群体。

“Seizures are unpredictable, and many patients are often unaware of them. Established EEG tools for objectively assessing seizure burden have been limited by monitoring duration, as in ambulatory EEG, or by cost and an unnatural setting, as in inpatient video EEG monitoring,” said Dr. Daniel Friedman, MD, Professor and Director, Division of Epilepsy, NYU Langone Health.

“癫痫发作具有不可预测性，许多患者往往对此毫无察觉。目前用于客观评估癫痫负担的既定脑电图工具，要么受限于监测时长（如动态脑电图），要么受限于成本及非自然的环境（如住院视频脑电图监测）。”纽约大学朗格尼健康中心癫痫科教授兼主任丹尼尔·弗里德曼医学博士表示。

“REMI provides a new solution for diagnosis and disease tracking on clinically relevant timescales of days to weeks, in a patient-friendly, convenient way.”.

“REMI 提供了一种新的解决方案，以患者友好且便捷的方式，在数天至数周的临床相关时间尺度上进行诊断和疾病追踪。”

With the closing of this round, Epitel is poised to deepen its clinical footprint across the United States. By easing the clinical burden on neurologists and enhancing patient adherence through a truly wireless experience, Epitel aims to redefine the standard of care for millions by making EEG accessible and equitable.

随着本轮融资的完成，Epitel 准备深化其在美国的临床布局。通过减轻神经科医生的临床负担，并通过真正的无线体验提高患者的依从性，Epitel 旨在让脑电图（EEG）检查更加普及和公平，从而为数百万人重新定义护理标准。

Epitel aims to redefine the standard of care for the millions of individuals living with epilepsy and other neurological conditions..

Epitel 旨在重新定义数百万癫痫及其他神经系统疾病患者的护理标准。

“The ambulatory EEG market has needed this kind of disruption for decades, and Epitel has built the right solution at the right moment,” said Joshua Phillips, Founder and Managing Partner, Catalyst Health Ventures, as well as Chairman of the Epitel Board of Directors. “This round gives the team the runway to move fast and meet the demand that's already there.

“动态脑电图市场几十年来一直需要这样的颠覆性创新，而Epitel在恰当的时刻推出了正确的解决方案，”Catalyst Health Ventures的创始人兼管理合伙人、Epitel董事会主席Joshua Phillips表示。“本轮融资为团队提供了充足的资金缓冲，使其能够快速行动，满足既有的市场需求。”

The technology is groundbreaking, but what really positions Epitel to transform brain health monitoring care is their clarity of purpose.'.

这项技术具有开创性，但真正使Epitel能够变革脑健康监测护理的是其明确的目标。

About Epitel

关于 Epitel

Epitel™ is a digital health company modernizing brain health solutions to improve patient care. By leveraging a proprietary cloud-based wearable sensor system and innovative AI technologies, Epitel empowers better treatment decisions by making EEG readily deployable and accessible. Headquartered in Salt Lake City, Epitel is dedicated to advancing neurological care across diverse healthcare settings.

Epitel™ 是一家数字健康公司，致力于现代化脑部健康解决方案，以改善患者护理。通过利用专有的云基可穿戴传感器系统和创新的人工智能技术，Epitel 使脑电图（EEG）更易于部署和获取，从而助力做出更优的治疗决策。Epitel 总部位于盐湖城，致力于在不同医疗环境中推动神经学护理的发展。

Visit www.epitel.com to learn more..

访问 www.epitel.com 了解更多信息。

Contacts

联系人

Media Contact:

媒体联系人：

Andrea Vuturo

安德烈亚·武图罗

Vuturo Group for Epitel, Inc.

Vuturo集团为Epitel公司

epitel@vuturo.com

epitel@vuturo.com

+1 (415) 689-8414

+1 (415) 689-8414

Source: businesswire.com

来源：businesswire.com